AstraZeneca/Daiichi Sankyo launches global phase 2 clinical trial: Enhertu treats HER2 mutant lung cancer

AstraZeneca and Daiichi Sankyo jointly announced recently that the global phase 2 clinical trial DESTINY-Lung02 has administered the first patient.

Lung cancer is the leading cause of cancer deaths in men and women, accounting for about one-fifth of global cancer deaths.

HER2 is a tyrosine kinase receptor, a growth-promoting protein that is expressed on the surface of a variety of tumors, including lung cancer, breast cancer, gastric cancer, and colorectal cancer.

At the end of January 2021, Daiichi Sankyo and AstraZeneca announced the DESTINY-Lung01 Phase II clinical trial of non-small cell lung cancer ( NSCLC) new data in the queue.

DESTINY-Lung01 Phase II trial cohort 1, enrolled patients with HER2 overexpression (defined as IHC3+ or IHC2+) metastatic NSCLC (n=49) who had previously received multiple regimens (chemotherapy, molecular targeted therapy, immunotherapy) ), the median number of these patients who received previous treatment options was 3, and most of them received platinum-based chemotherapy (91.

The results announced at the meeting showed that after review and evaluation by an independent center, patients with HER2 overexpression metastatic NSCLC who had previously received multiple treatment regimens received Enhertu (6.

Interim data from the DESTINY-Lung01 study HER2 mutation (HER2m) metastatic NSCLC cohort (n=42) was published at the 2020 American Society of Clinical Oncology (ASCO) online meeting and re-published at WCLC.

In recent years, the introduction of targeted therapies and checkpoint inhibitors has improved the treatment outcome of patients with advanced NSCLC.

In May 2020, the US FDA granted Enhertu Breakthrough Drug Designation (BTD) for the treatment of metastatic NSCLC patients who have progressed during or after platinum-containing chemotherapy and have HER2 mutations in their tumors.

Enhertu is a new-generation ADC drug that combines trastuzumab (trastuzumab), a humanized monoclonal antibody targeting HER2 with a new topoisomerase 1 inhibitor exatecan derivative ( DX-8951 derivatives, DXd) are linked together, which can target the delivery of cytotoxic agents to cancer cells.

In March 2019, AstraZeneca and Daiichi San reached a total value of US$6.

Up to now, Enhertu has been approved to treat 2 types of cancer: (1) For adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received at least 2 HER2 regimens.

Note: The original text has been deleted

Original source: DESTINY-Lung02 Phase 2 Trial of ENHERTU? Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung Cancer